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Well aware of Oscar Wilde’s admonition that ‘‘Consistency
is the last refuge of the unimaginative’’ I realize that calls
for improved measurement in dermatologic clinical research
have been consistent, persistent, and long-standing (Marks
et al, 1989; Chren, 1997, 2000; Charman et al, 2003). What
is the basis for this emphasis? Have things improved? What
are the current challenges and next steps for this field?
Accurate measurement is particularly important for der-
matologic clinical research. As in other fields, to document
the effects of our care and to compare care with different
therapies, we need accurate measurement tools for the
‘‘state’’ of a given skin condition. Measuring the state of the
skin is difficult, however. In general, our patients are
ambulatory, living with skin diseases rather than dying from
them; moreover, these diseases do not often affect con-
ventional laboratory values. Most importantly, we know
instinctively that the severity of a skin disease is often not
captured simply in its physical characteristics—its scale,
induration, erythema—but also includes aspects that can
be determined only by patients’ reports—pruritus, pain, ef-
fects on quality of life. Thus, our challenges are substantial:
we must measure not only what we see clinically (using
clinimetrics; Feinstein, 1987), but also patients’ reports of
their experiences (using psychometrics).
Tremendous progress has been made in clinical meas-
urement in dermatology, and two papers in this issue of the
Journal illustrate incremental advances in the field. Nijsten
et al (2005) studied the responses of a large US sample
with psoriasis to a common measure of disability from the
disease, the psoriasis disability index (PDI). Previous work
had documented that the instrument has evidence of
validity. These investigators performed a variety of other
psychometric analyses using classic methods as well as
less common evaluations such as Rasch analyses, which
are based on item response theory, a different approach to
modeling, scale construction, and scoring (Ware, 2003).
They conclude that the PDI may be suboptimal for
widespread use in patients with mild-to-moderate psoria-
sis, in part because of its relative insensitivity to lower levels
of disability, and the lack of evidence to support scoring the
instrument with a single global score.
In another paper, Hongbo et al (2005) provide evidence
to aid the interpretation of quality-of-life scores. This work
correlated patients’ scores on the Dermatology Life Quality
Index (DLQI) to their responses to a global question about
the effects of their skin disease on their lives. The analysis
permits a valid qualitative interpretation of DLQI scores as
indicating no, small, moderate, very large, or extremely
large effects on patients’ lives. Attaching clinical meaning to
psychometric scores is an important first step in making
these tools useful in clinical encounters.
These papers are important for several reasons. First,
both studies examine instruments that were developed and
refined by Andrew Finlay and his colleagues in Cardiff,
highlighting the seminal and sustained effects of their work
on improving the measurement of complex constructs in
dermatology. Second, the psychometric scrutiny to which
the instruments are subjected in these papers is emblem-
atic of the overall increase in the scientific rigor being
applied to dermatologic measurement in general. Finally,
the papers provide an opportunity to think about the ‘‘next
steps’’ in this field.
Psychometric scrutiny may subject assays for clinical
measurement to more compulsive standards than we use
for other, more conventional clinical tests such as radiologic
or histologic examinations (Sackett et al, 1991). On the oth-
er hand, these kinds of investigations raise legitimate ques-
tions and skepticism about some features of our clinical
measurement instruments. For example, among the con-
clusions of the Nijsten work was that disabling effects of
psoriasis are not unidimensional, questioning the validity
and usefulness of a single score as a measure of these
complex effects. This conclusion was based on data from
their psychometric analyses, but it has substantial face va-
lidity. Single scores, especially those that are merely calcu-
lated as sums or products, are attractive because they are
straightforward to compute, report, and compare among
different diseases and patient groups (Chren and Wein-
stock, 2004). But they may be suboptimal for at least two
reasons. First, they may be invalid for certain purposes, as
suggested by the Nijsten work. As these investigators state,
further validity testing is indicated to determine the dimen-
sions and complexity of what the PDI measures.
Second, single summative scores may also mask our
understanding of quality-of-life effects of diseases. This
point is illustrated by some of the data reported in the
Hongbo paper. Because the various ‘‘domains’’ of quality-
of-life effects are averaged for the DLQI score, a patient
who responded that her skin was itchy ‘‘very much’’ but wasAbbreviation: DLQI, dermatology life quality index
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not at all embarrassed or self-conscious, and who found the
other items ‘‘not relevant’’ would have a DLQI score of ‘‘3’’,
which would be interpreted as a ‘‘small effect’’ on her life.
This interpretation would hold even though she may have
been extremely depressed and worried from the persistent
itching, effects not measured by the DLQI. In fact, over 20%
of patients in the Hongbo study whose DLQI scores would
be interpreted as ‘‘small’’ responded that overall the effects
on their lives were moderate, very large, or extremely large.
Part of the explanation for this potentially important dis-
crepancy is that all effects measured by the DLQI—emo-
tional, functional, and physical—are averaged together into
a single score rather than a profile. Balancing the advan-
tages of a global score with the increased information of a
profile of scores, and also ensuring that the calculation of
global scores is based on psychometrically valid ‘‘weight-
ing’’ of component items and subscales, are important
challenges for quality-of-life measurement.
One of the most exciting aspects of research on im-
proved clinical measurement is its potential application to
improving our care of patients. This fact is particularly in-
triguing for dermatology, where the patient report is a vital
sign for dermatologic disease (Bierman, 2001; Chren et al,
2001). To treat a patient adequately we must also gauge
what he or she is experiencing; we need tools to measure
patient reports that are as reliable, valid, and interpretable
as tools to measure temperature, for example. In fact, John
Ware (2003) has noted the parallels between the develop-
ment of measures of complex aspects of health and the
evolution of thermometers. Both health and temperature are
hypothetical constructs that are challenging to assay. There
was variation and even controversy in the development of
the first thermometers, which used widely different scales.
Interestingly, Fahrenheit’s scaling and tool became popular
because he provided a reference point for interpretation—
the temperature of blood in a healthy person. Continued
research on refinement and interpretation of patients’
reports of skin diseases will permit clinicians to use this
information like a vital sign, to incorporate it into their clinical
encounter, enhancing their ability to understand and treat
skin diseases and improve patients’ lives.
This work was supported by an Independent Scientist Award (#K02 AR
02203-01) from the National Institute on Arthritis and Musculoskeletal
and Skin Disease, National Institutes of Health.
DOI: 10.1111/j.0022-202X.2005.23796.x
References
Bierman AS: Functional status: The six vital sign. J Gen Intern Med 16:785–786,
2001
Charman C, Chambers C, Williams H, et al: Measuring atopic dermatitis severity
in randomized controlled clinical trials: What exactly are we measuring? J
Invest Dermatol 120:932–941, 2003
Chren MM: Quality of care in dermatology. The state of (measuring) the art. Arch
Dermatol 133:1349–1351, 1997
Chren MM: Giving ‘‘scale’’ new meaning in dermatology: Measurement matters
[editorial; comment]. Arch Dermatol 136:788–790, 2000
Chren MM, Lasek RJ, Sahay AP, et al: Measurement properties of Skindex-16, A
brief quality-of-life measure for patients with skin diseases. J Cutan Med
Surg 5:105–110, 2001
Chren MM, Weinstock MA: Conceptual issues in measuring the burden of skin
diseases. J Investig Dermatol Symp Proc 9:97–100, 2004
Feinstein AR: Clinimetrics. New Haven: Yale University Press, 1987
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY: Translating the science
of quality of life into practice: What do dermatology life quality index
(DLQI) scores mean? J Invest Dermatol 125:659–664, 2005
Marks R, Barton SP, Shuttleworth D, et al: Assessment of disease progress in
psoriasis. Arch Dermatol 125:235–240, 1989
Nijsten T, Whalley D, Gelfand J, Margolis D, McKenna SP, Stern RS: The psy-
chometric properties of the psoriasis disability index in United States
patients. J Invest Dermatol 125:665–672, 2005
Sackett DL, Haynes RB, Guyatt GH, et al: Clinical Epidemiology. A Basic Science
for Clinical Medicine. Boston: Little, Brown and Company, 1991
Ware JE Jr: Conceptualization and measurement of health-related quality of life:
Comments on an evolving field. Arch Phys Med Rehabil 84 (Suppl. 2):
S43–S51, 2003
VITAL SIGNS FOR SKIN DISEASES ix125 : 4 OCTOBER 2005
